7/109 sources · 7 publishersUpdated Nov 22, 06:00 UTC
FDA misses Savara’s molgramostim review target with no new date
Savara said on November 20, 2026 that the FDA will not meet its November 22, 2026 PDUFA target for molgramostim’s Biologics License Application. The application seeks approval for treating autoimmune pulmonary alveolar proteinosis, and the FDA said its review remains ongoing. The agency provided no revised action date.
Why it matters
The missed target removes a scheduled regulatory catalyst and leaves the timing of a potential decision unresolved. Continued review means the announcement does not establish whether the FDA will approve or reject molgramostim.
Key facts
- 1The FDA will miss the November 22, 2026 PDUFA target date for Savara’s molgramostim application. tradingview.com
- 2The FDA’s review remains ongoing, and no revised action date was provided. tradingview.com
- 3Molgramostim is being reviewed for autoimmune pulmonary alveolar proteinosis. tradingview.com
Open questions
- The FDA did not disclose the reason for missing the target date.
- No material provides a new FDA action date.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.